Press Release Details
Collaboration of Four Biotech Companies Showcases High Throughput DNA Assembly Platform for Diverse Applications
The event, which is open to the public, will feature talks from leaders of each company as well as several demonstrations by Arzeda team members, aimed at educating attendees on how the platform transformed Arzeda's DNA construction. The platform can be adapted to other research environments and in turn can be a powerful tool for others in the industry to increase throughput and manufacturing speed while reducing production costs.
Arzeda will showcase several pilot examples of the platform including the following: Arzeda's DNA assembly platform was used to construct 822 plasmids encoding novel enzymes that were computationally designed to produce a new-to-market acrylate that could be used in the next generation of plexiglass and other industrial materials. The costs associated with constructing the plasmids were reduced by nearly 10-fold and the turnaround time decreased by 25 percent. Subsequent platform improvements have continued to reduce costs and turnaround times for other ongoing projects.
“Our Genetic Design-Build team at Arzeda established a high-throughput
DNA assembly platform which integrates Arzeda’s genetic design
software Scribe™, Twist’s high-quality DNA gene fragments, Labcyte’s
Echo® acoustic liquid handler and TeselaGen’s automated DNA assembly
design software and LIMS – in just six months,” said
The integrated platform supports the high-throughput testing of Arzeda’s computationally designed proteins and enzymes. After the proteins are designed, Arzeda proprietary genetic design software Scribe™ automatically encodes them into DNA. The resulting DNA sequences are then imported into TeselaGen’s Synthetic Evolution™ DESIGN software to automate the DNA assembly design process and determine the exact DNA fragments to be synthesized. TeselaGen’s software will soon be integrated with Twist’s API ordering system for seamless DNA ordering at scale. After the DNA is made by Twist and received, TeselaGen’s BUILD application automatically generates worklist instructions for the Echo Liquid Handler to perform the DNA assembly at miniaturized reaction volumes, reducing the use of expensive reagents.
“We are building a system that allows you to go from mind to molecule
very easily -- we help our clients move an idea for a bio-based product
out of their heads and into their hands quickly and efficiently,” said
"This collaboration of four leading companies in synthetic biology is a
perfect example of how Twist works in service of our customers,
providing large amounts of DNA rapidly to remove the bottleneck of DNA
synthesis to accelerate research and production," said Emily M.
Leproust, Ph.D., CEO and cofounder of
“Collaborating with industry partners to bring innovative capabilities
to our customers is an important focus for us,” said
Labcyte, now a part of Beckman Coulter Life Sciences, is revolutionizing liquid handling. Echo® Liquid Handlers use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 63 U.S. patents and others internationally. For more information, visit www.labcyte.com or www.beckman.com.
TeselaGen is building a deep learning-powered solution for rapid,
precise and accurate DNA making and modification. TeselaGen's
cloud-based enterprise platform bridges the gap between good ideas and
the realization of valuable products like vaccines, biologic medicines,
and sustainably sourced chemicals. Positioned at the intersection of
design and biology, TeselaGen is applying forward engineering approaches
to design, build and test in the biological realm. TeselaGen is
privately held and is based in the software hub of
Since 2008 Arzeda, The Protein Design Company™, has harnessed the power of computational protein design to build novel enzymes and discover new pathways that enable cost effective, sustainable production of value-added specialty chemicals and ingredients. In partnership with Fortune 500 companies and industrial leaders, the company has developed a portfolio of proteins that increase the efficiency, robustness and diversity of biological processes. Our proprietary pathway design software unlocks new opportunities for specialty chemicals, advanced materials and health and nutrition products that would otherwise be impossible to exploit. More information is available at www.arzeda.com. Arzeda is on Twitter. Sign up to follow our Twitter feed @ArzedaCo at https://twitter.com/ArzedaCo.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements
other than statements of historical facts contained herein are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, the potential promise of Twist Bioscience’s
manufacturing synthetic DNA at increased scale and complexity. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking statements.
Such risks and uncertainties include, among others, the risks and
uncertainties of the ability to attract new customers and retain and
grow sales from existing customers; risks and uncertainties of rapidly
changing technologies and extensive competition in synthetic biology
could make the products
For Twist Bioscience:
Michael Fero, Ph.D.